$Elevai Labs, Inc.(ELAB)$ Elevai Labs (ELAB) announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio (INMB). The licensing agreement grants Elevai a license to use INmune Bio's proprietary "EMx" technology, developed by INmune Bio, Inc., CMO, Mark Lowdell, PhD, that enables Elevai to manufacture current Good Manufacturing Practice grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.... They are seeking more expansion, and you know what it means...
Comments